CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 8 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02058940
NCT02058940Phase 4Completed
CompareCT.gov

Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury

University of North Carolina, Chapel Hill·interventional·Posted Feb 10, 2014·Updated Jul 12, 2018

In Brief

A Phase 4 clinical trial evaluating Exenatide for Brain Injuries. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Injuries
CountriesUnited States
CollaboratorsAstraZeneca, Medtronic

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2014
Enrollment StartAug 1, 2015
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.4 years ago

Interventions

Exenatidedrug

50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours